Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Moxonidine 0.2 mg Tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹95/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Moxonidine 0.2 mg Tablet is a centrally acting antihypertensive medication from the imidazoline receptor agonist class. It selectively stimulates imidazoline I₁ receptors in the brainstem, reducing sympathetic nervous system activity, which results in lowered vascular resistance and blood pressure. Unlike older central antihypertensives such as clonidine, Moxonidine offers high blood pressure control with fewer sedative and anticholinergic effects due to its selectivity. The 0.2 mg strength is typically used as the starting dose for patients initiating therapy and can be titrated upwards based on response. Moxonidine is particularly useful in patients with metabolic syndrome, insulin resistance, or type 2 diabetes, as it has minimal impact on glucose and lipid metabolism. It provides smooth 24-hour blood pressure control with once-daily dosing and is well tolerated as monotherapy or in combination with other antihypertensives.
Common side effects include dizziness, headache, fatigue, dry mouth, and mild drowsiness, particularly during the first few days of treatment. Some patients may experience gastrointestinal discomfort or insomnia. Rarely, bradycardia, significant hypotension, or allergic reactions can occur. Most side effects are transient and subside as the body adapts to the medication.
Moxonidine 0.2 mg Tablet is indicated for the management of essential hypertension in adults, especially in patients who are not controlled with or intolerant to conventional antihypertensive medications, or those with metabolic comorbidities.
Moxonidine 0.2 mg should only be taken under medical supervision. It is contraindicated in patients with severe bradycardia, sick sinus syndrome, heart block, or advanced heart failure unless prescribed by a specialist. Dose should be tapered gradually when discontinuing to avoid rebound hypertension. Caution is advised in patients with impaired renal function; dose adjustment may be necessary. The drug is not recommended during pregnancy or breastfeeding unless the potential benefits outweigh the risks. Alcohol should be limited as it can enhance drowsiness and the hypotensive effect. Regular blood pressure monitoring and follow-up are essential during treatment to ensure safety and efficacy.
Store Moxonidine 0.2 mg Tablet in a cool, dry place below 30°C. Protect from direct sunlight and moisture. Keep the tablets in their original blister packaging and out of reach of children. Do not use beyond the expiry date printed on the strip.
Composition : Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75mg + Rosuvastatin 20mg + Clopidogrel 150mg Tablet
Composition : Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg capsule
Composition : Rosuvastatin Calcium IP eq. to Rosuvastatin (as pellets) 20 mg. + Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg. Excipients q.s.
Composition : Rosuvastatin 5 mg tablet
Composition : Rosuvastatin 5mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 40 mg tablet
Composition : Rosuvastatin (20mg) tablet
Composition : Rosuvastatin 20 mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 20mg + Clopidogrel 75mg Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Moxonidine Tablets have strong demand in the cardiology and antihypertensive segment, making them a valuable specialty-care product for pharma distributors, wholesalers, and franchise partners. It is widely prescribed for essential hypertension and long-term cardiovascular risk management, ensuring consistent prescription-driven demand.
Medical distributors and agencies benefit from the rising prevalence of hypertension and cardiovascular disorders. Helps effectively control high blood pressure (hypertension) Acts centrally to regulate sympathetic nervous system activity Commonly prescribed for patients requiring additional antihypertensive support Widely used by cardiologists and general physicians Supports long-term cardiovascular risk reduction Suitable for chronic hypertension management Strong demand in hospital, clinic, and retail pharmacy segments This makes it a high-value antihypertensive product with strong repeat prescription potential.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Moxonidine 0.2 mg Tablets with monopoly rights, promotional support, quality manufacturing standards, attractive packaging, and competitive pricing for distributors and wholesalers
Wholesalers and franchise partners benefit from steady cardiology prescription demand, long-term patient adherence, strong physician confidence, and stable year-round turnover in the cardiovascular segment.
Interested distributors, stockists, and pharma franchise partners can contact Cafoli LifeCare Pvt Ltd to discuss monopoly territory rights, pricing structure, marketing support, and complete cardiology and antihypertensive product portfolio access to build a strong presence in the cardiovascular healthcare market.